APOA1 Oxidation is Associated to Dysfunctional High-density Lipoproteins in Human Abdominal Aortic Aneurysm
Overview
Authors
Affiliations
Background: High-density lipoproteins (HDL) are a complex mixture of lipids and proteins with vasculoprotective properties. However, HDL components could suffer post-translational modifications (PTMs) under pathological conditions, leading to dysfunctional HDL. We studied whether HDL are modified in abdominal aortic aneurysm (AAA) and the effect on HDL functionality.
Methods: HDL were isolated by ultracentrifugation from AAA tissue (HDL-T) and from plasma of healthy volunteers and then incubated with AAA tissue-conditioned medium (HDL-AAA CM). PTMs from these particles were characterized using Comet-PTM. The ability of HDL-AAA CM for promoting cholesterol efflux was determined ex vivo and in vivo by using J774A.1 [H]cholesterol-labeled mouse macrophages and after injecting [H]cholesterol-labeled mouse macrophages and HDL into the peritoneal cavity of wild-type C57BL/6 mice, respectively. Trp50 and Trp108 oxidized forms of APOA1 in HDL incubated with conditioned-medium of activated neutrophils and in plasma of AAA patients and controls were measured by targeted parallel reaction monitoring.
Findings: Oxidation was the most prevalent PTM in apolipoproteins, particularly in APOA1. Trp50 and Trp108 in APOA1 were the residues most clearly affected by oxidation in HDL-T and in HDL-AAA CM, when compared to their controls. In addition, cholesterol efflux was decreased in macrophages incubated with HDL-AAA CM in vitro and a decreased macrophage-to-serum reverse cholesterol transport was also observed in mice injected with HDL-AAA CM. Finally, both oxidized Trp50 and Trp108 forms of APOA1 were increased in HDL incubated with conditioned-medium of activated neutrophils and in plasma of AAA patients in relation to controls.
Interpretation: Oxidative modifications of HDL present in AAA tissue and plasma were closely associated with the loss of vasculoprotective properties of HDL in AAA. FUND: MINECO, ISCiii-FEDER, CIBERDEM, CIBERCV and LA CAIXA.
Kempegowda S, Sugur K, Thimmulappa R J Cardiovasc Transl Res. 2024; 18(1):169-184.
PMID: 39298091 DOI: 10.1007/s12265-024-10559-x.
Molto E, Pintado C, Andrade Louzada R, Bernal-Mizrachi E, Andres A, Gallardo N Int J Mol Sci. 2023; 24(22).
PMID: 38003361 PMC: 10671570. DOI: 10.3390/ijms242216172.
Sorokin A, Hong C, Aponte A, Florida E, Tang J, Patel N JCI Insight. 2023; 8(20.
PMID: 37698922 PMC: 10619497. DOI: 10.1172/jci.insight.172893.
Rani A, Marsche G Pharmaceutics. 2023; 15(5).
PMID: 37242746 PMC: 10221824. DOI: 10.3390/pharmaceutics15051504.
Kazamia R, Keravnou A, Moushi A, Sokratous K, Michailidou K, Yiangou K BMC Cardiovasc Disord. 2023; 23(1):138.
PMID: 36922793 PMC: 10018995. DOI: 10.1186/s12872-023-03154-6.